Program
sitagliptin
Also written as “Sitagliptin”, “sitagliptin phosphate” and “Sitagliptin phosphate”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Glucose Intolerance · Renal Insufficiency · Hepatic Insufficiency, led by 11 companies.
Drug pageSitagliptin: every studyMany companies study it; this page follows only the 101 they lead. All 306 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 780 open or running | phase 4since Jan 28, 2009 | Jul 2, 2004 | none ahead |
| Ono Pharmaceuticalits history only | 50 open or running | phase 3since Aug 11, 2006 | Aug 11, 2006 | none ahead |
| ADIUMits history only | 40 open or running | no phasesince Aug 10, 2026 | Aug 10, 2026 | none ahead |
| Novo Nordiskits history only | 40 open or running | phase 4since Jan 24, 2012 | Jun 18, 2008 | none ahead |
| Bio-innovaits history only | 22 open or running | phase 1since Dec 15, 2023 | Dec 15, 2023 | none ahead |
| Novartis | 20 open or running | phase 4since Sep 13, 2012 | Jun 12, 2012 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 20 open or running | phase 2since Aug 28, 2013 | Aug 28, 2013 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 1since Jun 30, 2016 | Jun 30, 2016 | none ahead |
| Dong Wha Pharmaceuticalits history only | 10 open or running | phase 1since May 4, 2022 | May 4, 2022 | none ahead |
| Getz Pharmaits history only | 10 open or running | phase 4since Nov 29, 2021 | Nov 29, 2021 | none ahead |
| KineMedits history only | 10 open or running | no phasesince Mar 23, 2010 | Mar 23, 2010 | none ahead |
Also a collaborator on its studies: Parexel, Pfizer, Bristol-Myers Squibb and Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 12, 2012First study: phase 2 study in Diabetes Mellitus, Type 2First studyNCT01619332 · 220 enrolled · United States
- Sep 13, 2012Phase 4 study in Diabetes Mellitus, Type 2NCT01686932 · 51 enrolled · Germany
- Jul 21, 2022Named sitagliptinINNProposed as its International Nonproprietary Name in WHO's List 127
TargetBeta
“Dipeptidyl peptidase IV inhibitor; Dipeptidyl peptidase IV inhibitor; Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule
Other programs on DPP4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Linagliptinrule | Boehringer Ingelheim | phase 4 | 96 |
| gemigliptinrule | LG Chem | phase 4 | 30 |
| anagliptinrule | JW Pharmaceutical | phase 4 | 6 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
| cofrogliptinrule | Haisco Pharmaceutical Group | no phase | 1 |
Studies
All 2 Novartis leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01686932Diabetes Mellitus, Type 2 · Germany | 4 | Completed | Sep 2014 | 51 |
| NCT01619332Diabetes Mellitus, Type 2 · United States | 2 | Completed | Sep 2013 | 220 |
How it is read
Names in the registry
- “Sitagliptin”, 33 entries
- “sitagliptin phosphate”, 18 entries
- “sitagliptin”, 15 entries
- “Sitagliptin phosphate”, 10 entries
- “Sitagliptin/Metformin FDC”, 5 entries
Codes read as this program: MK0431.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 106 studies
- Diabetes Mellitus, 2 studies
- Glucose Intolerance, 1 study
- Renal Insufficiency, 1 study
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.